Stocks · News reference

EXCLUSIVE: Scienture Revenue Soars 256% As Drugmaker Targets 2027 Profitability

Oct 13, 2026, 11:45 AMVandana Singh

Scienture Holdings reports Q3 revenue of $1.22M, up 256% QoQ, driven by Arbli growth and the launch of Rezenopy.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

Fiscal.aiOct 22, 2026, 1:04 PM
Scienture Holdings Issues Shareholder Letter Highlighting Financial and Commercial Progress
Scienture Holdings, Inc. released a letter to shareholders detailing a 256% sequential revenue growth for the first nine months of 2026 and progress toward 2027 profitability.
SCNX
SEC EDGAROct 19, 2026, 8:05 PMSEC EDGAR
8-K filing — Scienture Holdings, Inc. (SCNX)
Filed: 2026-10-19 AccNo: 0001493152-26-047579 Size: 269 KB Item 2.02: Results of Operations and Financial Condition Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Item 9.01: Financial Statements and Exhibits
SCNX
BenzingaOct 13, 2026, 6:51 PMBenzinga Newsdesk
Scienture Holding shares are trading lower despite reporting preliminary Q3 revenue of $1.22 million, up 256% sequentially.
SCNX
BenzingaOct 13, 2026, 12:08 PMBenzinga Newsdesk
SCIENTURE HOLDINGS Reports Preliminary Q3 Revenue Of ~$1.22M
SCIENTURE HOLDINGS, INC. (NASDAQ:SCNX) ("Scienture"), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers
SCNX